SX-682

SX-682 is an orally bioavailable, potent small-molecule dual inhibitor of the chemokine receptors CXCR1 and CXCR2. These receptors are pivotal in the recruitment of myeloid-derived suppressor cells (MDSCs), which create an immunosuppressive tumor microenvironment that shields cancer cells from immune surveillance and promotes metastasis. By selectively and reversibly antagonizing both CXCR1 and CXCR2, SX-682 disrupts this immunosuppressive "cloak," thereby enhancing anti-tumor immune responses by liberating effector T cells and natural killer cells to attack cancer. The drug has demonstrated single-agent activity as well as synergy with checkpoint inhibitors in preclinical models. It is being developed primarily for oncology indications including metastatic melanoma, non-small cell lung cancer, prostate cancer, colorectal cancer, myelodysplastic syndromes, and others[1][2][7].

Other names

2-(2-dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amideBoronic acid, b-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)